Safety and efficacy of everolimus-versus sirolimus-eluting stents: A systematic review and meta-analysis of 11 randomized trials

American Heart Journal

Volumn 165, Issue 2, 2013, Pages

  Park, Kyung Woo ^a   Kang, Si Hyuck ^a   Velders, Matthijs A ^b   Shin, Dong Ho ^a   Hahn, Seokyung ^a,c   Lim, Woo Hyun ^a   Yang, Han Mo ^a   Lee, Hae Young ^a   Van Boven, Adrianus J ^b   Hofma, Sjoerd H ^b   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Oh, Byung Hee ^a   Park, Young Bae ^a   Kandzari, David E ^d   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

^c Seoul National University College of Medicine   (South Korea)

^d PIEDMONT HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYPHER; EVEROLIMUS; PROMUS; RAPAMYCIN; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR RISK; CORONARY ARTERY RECANALIZATION; DEVICE SAFETY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; REVIEW; RISK REDUCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW;

EID: 84872840773     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.08.007     Document Type: Article

References (28)

1. K.W. Park, J.H. Yoon, and J.S. Kim Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial Am Heart J 157 5 2009 811 817 e1
2. K.W. Park, I.H. Chae, and D.S. Lim Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial J Am Coll Cardiol 58 18 2011 1844 1854
3. S. Windecker, A. Remondino, and F.R. Eberli Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization N Engl J Med 353 7 2005 653 662
4. A. Kastrati, A. Dibra, and S. Eberle Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials JAMA 294 7 2005 819 825
5. A. Schomig, A. Dibra, and S. Windecker A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease J Am Coll Cardiol 50 14 2007 1373 1380
6. A. Kastrati, J. Mehilli, and J. Pache Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 10 2007 1030 1039
7. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 10 2007 998 1008
8. A.V. Finn, G. Nakazawa, and M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 7 2007 1500 1510
9. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). In: Higgins JP, Green S, editors.: The Cochrane Collaboration (http://www.cochrane-handbook.org/); 2011.
10. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 17 2007 2344 2351
11. S. Gillen, T. Schuster, and C. Meyer Zum Buschenfelde Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages PLoS Med 7 4 2010 e1000267
12. N. Mantel, and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 4 1959 719 748
13. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188
14. J.P. Higgins, S.G. Thompson, and J.J. Deeks Measuring inconsistency in meta-analyses BMJ 327 7414 2003 557 560
15. C. Kaiser, S. Galatius, and P. Erne Drug-eluting versus bare-metal stents in large coronary arteries N Engl J Med 363 24 2010 2310 2319
16. W.J. Kim, S.W. Lee, and S.W. Park Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial Circulation 124 8 2011 886 892
17. R.A. Byrne, A. Kastrati, and S. Massberg Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial J Am Coll Cardiol 58 13 2011 1325 1331
18. L. Okkels Jensen, P. Thayssen, and H.S. Hansen Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) Circulation 125 10 2012 1246 1255
19. F. Burzotta, C. Trani, and D. Todaro Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach JACC Cardiovasc Interv 4 3 2011 327 335
20. D.W. Park, Y.H. Kim, and H.G. Song Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial JACC Cardiovasc Interv 4 10 2011 1096 1103
21. T. Sakakibara, H. Ishii, and T. Toriyama Sirolimus-Eluting Stent vs. Everolimus-Eluting Stent for Coronary Intervention in Patients on Chronic Hemodialysis Circ J 2011
22. T. Kimura, T. Morimoto, and M. Natsuaki Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) Circulation 2012
23. S.H. Hofma, J. Brouwer, and M.A. Velders Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus-Eluting Stents in Acute Myocardial Infarction J Am Coll Cardiol 60 5 2012 381 387
24. Velders MA, Boven AJV, Hofma SH. Xience V stent vs. Cypher stent in all-comer patients: A randomized trial. In: Unpublished Work; 2012.
25. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbæk H, Tilsted HH, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. The Lancet;375(9720):1090-1099.
26. A. de Waha, A. Dibra, and R.A. Byrne Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials Circ Cardiovasc Interv 4 4 2011 371 377
27. R. Sedrani, S. Cottens, and J. Kallen Chemical modification of rapamycin: the discovery of SDZ RAD Transplant Proc 30 5 1998 2192 2194
28. M. Joner, G. Nakazawa, and A.V. Finn Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents J Am Coll Cardiol 52 5 2008 333 342